Table 4.
Multivariable model for predictors of mortality stratified by year of diagnosis.
| 1998–2002 | 2003–2007 | 2008–2012 | |
|---|---|---|---|
|
| |||
| aHR (95% CI) | aHR (95% CI) | aHR (95% CI) | |
| Race | |||
| White | Referent | Referent | Referent |
| Black | 1.34 (1.14–1.58)* | 1.22 (1.04–1.43)* | 0.96 (0.77–1.19) |
| Age | |||
| <35 | Referent | Referent | Referent |
| 35–39 | 1.16 (0.90–1.50) | 0.92 (0.70–1.21) | 1.19 (0.85–1.66) |
| 40–44 | 1.38 (1.09–1.75)* | 1.08 (0.85–1.37) | 0.98 (0.72–1.33) |
| 45–49 | 1.55 (1.23–1.96)* | 1.19 (0.96–1.49) | 1.17 (0.87–1.56) |
| Year of diagnosis | 1.00 (0.97–1.04) | 0.99 (0.95–1.03) | 0.99 (0.92–1.07) |
| Insurance status | |||
| Private | Referent | Referent | Referent |
| Medicare | 2.56 (2.03–3.22)* | 2.27 (1.84–2.80)* | 2.07 (1.51–2.82)* |
| Medicaid | 1.58 (1.30–1.92)* | 1.67 (1.40–1.99)* | 1.52 (1.22–1.90)* |
| Other government/unknown | 1.09 (0.85–1.40) | 0.89 (0.61–1.30) | 1.65 (1.08–2.54)* |
| Uninsured | 1.50 (1.21–1.85)* | 1.61 (1.32–1.96)* | 1.46 (1.08–1.98)* |
| Income | |||
| <$38,000 | Referent | Referent | Referent |
| $38,000–$47,999 | 0.83 (0.71–0.97)* | 0.83 (0.71–0.98)* | 1.03 (0.81–1.30) |
| $48,000–$62,999 | 0.75 (0.63–0.88)* | 0.84 (0.71–0.997)* | 0.84 (0.66–1.07) |
| $63,000+ | 0.67 (0.56–0.79)* | 0.63 (0.53–0.75)* | 0.78 (0.60–1.003) |
| Unknown | 1.09 (0.75–1.59) | 1.44 (0.95–2.17) | 1.70 (0.87–3.33) |
| Location | |||
| Metropolitan | Referent | Referent | Referent |
| Urban | 0.98 (0.82–1.16) | 0.90 (0.75–1.07) | 1.02 (0.83–1.26) |
| Rural | 1.03 (0.68–1.57) | 1.24 (0.85–1.83) | 1.00 (0.56–1.79) |
| Unknown | 1.00 (0.71–1.40) | 0.94 (0.65–1.35) | 1.33 (0.77–2.31) |
| Charlson/Deyo comorbidity score | |||
| 0 | – | Referent | Referent |
| 1 | – | 1.24 (1.06–1.45)* | 1.48 (1.20–1.83)* |
| ≥2 | – | 2.34 (1.78–3.08)* | 1.56 (1.06–2.28)* |
| Facility type | |||
| Academic/research | Referent | Referent | Referent |
| Community cancer | 1.01 (0.83–1.23) | 1.00 (0.81–1.24) | 1.05 (0.79–1.40) |
| Comprehensive community cancer | 1.01 (0.89–1.14) | 0.93 (0.83–1.04) | 1.06 (0.91–1.24) |
| Other | 2.20 (1.79–2.72)* | –‡ | –‡ |
| Facility region | |||
| Eastern | Referent | Referent | Referent |
| Midwest | 1.06 (0.91–1.24) | 0.94 (0.81–1.10) | 0.97 (0.78–1.21) |
| South | 1.13 (0.96–1.33) | 1.06 (0.91–1.24) | 1.06 (0.85–1.33) |
| West | 0.80 (0.65–0.97)* | 1.06 (0.88–1.28) | 0.93 (0.72–1.21) |
| Stage | |||
| IA | Referent | Referent | Referent |
| IB | 1.67 (1.29–2.17)* | 1.60 (1.18–2.19)* | 2.39 (1.63–3.52)* |
| INOS | 0.80 (0.45–1.42) | 0.99 (0.65–1.51) | 0.95 (0.49–1.86) |
| II | 1.31 (1.02–1.68)* | 1.67 (1.27–2.20)* | 2.00 (1.32–3.04)* |
| III | 1.97 (1.51–2.56)* | 2.98 (2.31–3.83)* | 3.87 (2.75–5.44)* |
| IV | 5.36 (4.03–7.14)* | 7.75 (6.13–9.80)* | 11.03 (7.75–15.69)* |
| Unknown | 1.68 (1.44–1.96)* | 1.91 (1.62–2.26)* | 2.88 (2.18–3.82)* |
| Histology | |||
| Endometrioid | Referent | Referent | Referent |
| Serous | 0.77 (0.54–1.09) | 1.31 (0.99–1.74) | 1.54 (1.08–2.21)* |
| Clear Cell | 1.02 (0.66–1.58) | 1.07 (0.63–1.84) | 1.57 (0.83–2.98) |
| Sarcoma | 2.28 (1.91–2.72)* | 3.00 (2.55–3.54)* | 2.90 (2.38–3.52)* |
| Other/not otherwise specified | 0.97 (0.85–1.11) | 1.25 (1.06–1.48)* | 1.44 (1.06–1.94)* |
| Grade | |||
| Well | Referent | Referent | Referent |
| Moderate | 1.64 (1.41–1.90)* | 1.81 (1.51–2.17)* | 1.93 (1.46–2.54)* |
| Poorly | 3.63 (3.07–4.29)* | 3.84 (3.23–4.56)* | 5.64 (4.27–7.44)* |
| Unknown | 2.23 (1.88–2.65)* | 2.06 (1.70–2.50)* | 2.66 (2.02–3.52)* |
| Radiation | |||
| None | Referent | Referent | Referent |
| Brahytherapy | 0.84 (0.61–1.16) | 0.73 (0.55–0.95)* | 0.66 (0.49–0.88)* |
| External beam | 1.22 (1.06–1.40)* | 0.90 (0.77–1.04) | 0.91 (0.73–1.13) |
| Unknown | –‡ | 0.95 (0.55–1.64) | 0.63 (0.10–4.02) |
| Chemotherapy | |||
| Yes | Referent | Referent | Referent |
| No | 0.47 (0.40–0.56)* | 0.56 (0.48–0.65)* | 0.60 (0.48–0.75)* |
| Unknown | 0.39 (0.26–0.59)* | 0.45 (0.31–0.65)* | 0.53 (0.27–1.02) |
Marginal Cox proportional hazard models included race, age, year of diagnosis, insurance status, income, location, comorbidity, facility type, region, stage, histology, grade, radiation and chemotherapy accounting for facility-level clustering. In the stratum of 1998–2002, comorbidity was not adjusted for because all patients were unknown. In the stratum of 2008–2012, 2 patients in 2009 and 2,667 patients in 2012 were excluded because of missing follow-up time or vital status.
NOS: not otherwise specified. aHR: adjusted hazard ratio. CI: confidence interval.
*
P-value < 0.05.
‡
Non-estimable.